Literature DB >> 6834850

Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer.

P Schick, J Goodstein, J Moor, J Butler, K L Senter.   

Abstract

Six patients with advanced local-regional breast cancer were reviewed. Five out of the six patients previously had had radiation therapy as part of the initial therapy. All patients had preoperative cycles of combination chemotherapy, either CMF or CAF. The two stage III patients had greater than 75% reduction in measurable tumor mass, which allowed a conventional modified radical or radical mastectomy to be performed. Both of these patients are now disease free at 26 and 27 months. The four stage IV patients had lesser operations following the chemotherapy (two simple mastectomies, one simple mastectomy plus axillary resection, and one axillary debulking). Reconstruction utilized advancement flaps in three patients and split-thickness skin grafts in the other. None of the patients had postoperative wound problems, and none of the patients had further problems with local cancer control. All patients had combination chemotherapy starting two to six weeks following surgery. Preoperative chemotherapy followed by surgery plays an important role in management of locally advanced stage III and stage IV breast cancer.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6834850     DOI: 10.1002/jso.2930220415

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  5 in total

Review 1.  Locally advanced breast cancer in developing countries: the place of surgery.

Authors:  Justus P Apffelstaedt
Journal:  World J Surg       Date:  2003-06-06       Impact factor: 3.352

2.  Influence of patient, physician, and hospital characteristics on the receipt of guideline-concordant care for inflammatory breast cancer.

Authors:  Ryan A Denu; John M Hampton; Adam Currey; Roger T Anderson; Rosemary D Cress; Steven T Fleming; Joseph Lipscomb; Susan A Sabatino; Xiao-Cheng Wu; J Frank Wilson; Amy Trentham-Dietz
Journal:  Cancer Epidemiol       Date:  2015-11-21       Impact factor: 2.984

3.  Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.

Authors:  Jiaqiang Zhang; Chang-Yun Lu; Ho-Min Chen; Szu-Yuan Wu
Journal:  JAMA Netw Open       Date:  2021-03-01

4.  Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer.

Authors:  Pat Whitworth; Peter D Beitsch; James V Pellicane; Paul L Baron; Laura A Lee; Carrie L Dul; Charles H Nash; Mary K Murray; Paul D Richards; Mark Gittleman; Raye Budway; Rakhshanda Layeequr Rahman; Pond Kelemen; William C Dooley; David T Rock; Ken Cowan; Beth-Ann Lesnikoski; Julie L Barone; Andrew Y Ashikari; Beth Dupree; Shiyu Wang; Andrea R Menicucci; Erin B Yoder; Christine Finn; Kate Corcoran; Lisa E Blumencranz; William Audeh
Journal:  Ann Surg Oncol       Date:  2022-04-04       Impact factor: 4.339

Review 5.  Preoperative chemotherapy for women with operable breast cancer.

Authors:  J S D Mieog; J A van der Hage; C J H van de Velde
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.